Efficacy of Three Toothpastes Using an in Situ Caries Model

NCT ID: NCT02751320

Last Updated: 2017-10-13

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

58 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-02-01

Study Completion Date

2016-08-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This will be a single-centre, randomized, blinded, placebo-controlled, 6-treatment, 4-period crossover, incomplete block design, in situ caries study in healthy adults who wear a removable bilateral mandibular partial denture. The denture will be modified to accommodate 4 gauze-covered specimens of human dental enamel (4x3mm) that have been previously demineralized in vitro to form either S or low-R lesions (2 specimens of each lesion type will be used with each participant). After 14 days of twice daily product use off-site, the 2 S lesion specimens will be removed at the study site, with the remaining 2 low-R lesion specimens removed at the study site after a further 14 days of product use. To determine the remineralization ability of the treatments, all specimens will be analyzed by transverse microradiography (TMR) and enamel fluoride uptake (EFU), with the S lesions additionally analyzed by surface micro hardness (SMH) and the low-R lesions additionally analyzed by quantitative light fluorescence (QLF).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dental Caries

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Experimental Dentifrice1

Participants will brush their natural teeth with a pre-wetted toothbrush and their assigned dentifrice for one timed minute, ensuring the enamel specimens retained within their mouths are not directly brushed. Participants should then rinse their mouths with 15ml of tap water for approximately 10s.

Group Type EXPERIMENTAL

0.425 % w/w phytate,1150ppm F

Intervention Type DRUG

Participants were assigned with 1.5±0.1g twice daily dentifrice for one timed minute.

Experimental Dentifrice 2

Participants will brush their natural teeth with a pre-wetted toothbrush and their assigned dentifrice for one timed minute, ensuring the enamel specimens retained within their mouths are not directly brushed. Participants should then rinse their mouths with 15ml of tap water for approximately 10s.

Group Type EXPERIMENTAL

0.85 % w/w phytate,1150ppm F

Intervention Type DRUG

Participants were assigned with 1.5±0.1g twice daily dentifrice for one timed minute.

Experimental Dentifrice 3

Participants will brush their natural teeth with a pre-wetted toothbrush and their assigned dentifrice for one timed minute, ensuring the enamel specimens retained within their mouths are not directly brushed. Participants should then rinse their mouths with 15ml of tap water for approximately 10s.

Group Type EXPERIMENTAL

0.85 % w/w phytate,0.3%ZnCl2 0.5% sodium citrate, 1150ppm F

Intervention Type DRUG

Participants were assigned with 1.5±0.1g twice daily dentifrice for one timed minute.

Reference Product 1

Participants will brush their natural teeth with a pre-wetted toothbrush and their assigned dentifrice for one timed minute, ensuring the enamel specimens retained within their mouths are not directly brushed. Participants should then rinse their mouths with 15ml of tap water for approximately 10s.

Group Type PLACEBO_COMPARATOR

0 ppm F

Intervention Type OTHER

Participants were assigned with 1.5±0.1g twice daily dentifrice for one timed minute.

Reference Product 2

Participants will brush their natural teeth with a pre-wetted toothbrush and their assigned dentifrice for one timed minute, ensuring the enamel specimens retained within their mouths are not directly brushed. Participants should then rinse their mouths with 15ml of tap water for approximately 10s.

Group Type ACTIVE_COMPARATOR

1150ppm F

Intervention Type DRUG

Participants were assigned with 1.5±0.1g twice daily dentifrice for one timed minute.

Reference Product 3

Participants will brush their natural teeth with a pre-wetted toothbrush and their assigned dentifrice for one timed minute, ensuring the enamel specimens retained within their mouths are not directly brushed. Participants should then rinse their mouths with 15ml of tap water for approximately 10s.

Group Type ACTIVE_COMPARATOR

0.3%ZnCl2, 0.5% sodium citrate, 1150ppm F

Intervention Type DRUG

Participants were assigned with 1.5±0.1g twice daily dentifrice for one timed minute.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

0.425 % w/w phytate,1150ppm F

Participants were assigned with 1.5±0.1g twice daily dentifrice for one timed minute.

Intervention Type DRUG

0.85 % w/w phytate,1150ppm F

Participants were assigned with 1.5±0.1g twice daily dentifrice for one timed minute.

Intervention Type DRUG

0.85 % w/w phytate,0.3%ZnCl2 0.5% sodium citrate, 1150ppm F

Participants were assigned with 1.5±0.1g twice daily dentifrice for one timed minute.

Intervention Type DRUG

0 ppm F

Participants were assigned with 1.5±0.1g twice daily dentifrice for one timed minute.

Intervention Type OTHER

1150ppm F

Participants were assigned with 1.5±0.1g twice daily dentifrice for one timed minute.

Intervention Type DRUG

0.3%ZnCl2, 0.5% sodium citrate, 1150ppm F

Participants were assigned with 1.5±0.1g twice daily dentifrice for one timed minute.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Demonstrates understanding of the study.
2. Aged 18 to 85 years.
3. Understands and is willing, able and likely to comply with all study procedures and restrictions.
4. Has good general health (in the opinion of the investigator or medically qualified designee).
5. A salivary flow-rate in the range of normal values (unstimulated whole saliva flow- Rate ≥ 0.2 g/minute (min); gum base stimulated whole saliva flow-Rate ≥ 0.8 g/min).
6. Currently wearing a removable mandibular partial denture with sufficient room in the posterior buccal flange area to accommodate two enamel specimens.
7. Have no current active caries or periodontal disease and all restorations in a good state of repair.
8. Willing and capable of brushing their natural teeth with the lower partial denture in place.

Exclusion Criteria

1. Pregnant or breast feeding women.
2. Known or suspected intolerance or hypersensitivity to the study materials or their stated ingredients.
3. Currently taking antibiotics or have taken antibiotics in the two weeks prior to the screening visit.
4. Unable to measure product weights accurately using the assigned study scale as determined by the study staff as demonstrated.
5. Participation in another clinical study or receipt of an investigational drug within 30 days of the screening visit.
6. Have received a professional fluoride treatment within 14 days of randomization to the first treatment.
7. Recent history (within the last year) of alcohol or other substance abuse.
Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

GlaxoSmithKline

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

GSK Clinical Trials

Role: STUDY_DIRECTOR

GlaxoSmithKline

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

GSK Investigational Site

Indianapolis, Indiana, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

202301

Identifier Type: -

Identifier Source: org_study_id